Skip to main content

Bempedoic acid Pregnancy and Breastfeeding Warnings

Brand names: Nexletol

Bempedoic acid Pregnancy Warnings

Benefit should outweigh risk

US FDA pregnancy category: Not assigned

Risk Summary: There are no data available in human pregnancy to inform a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes; this drug may cause fetal harm based upon its mechanism of action.

Comments:
-This drug should be discontinued once pregnancy is recognized unless the benefits are expected to outweigh the potential risks to the fetus.
-According to some authorities, this drug is contraindicated during pregnancy; this drug should be discontinued prior to conception; women of childbearing potential should use effective contraception during treatment (UK).

Animal studies have not shown teratogenicity in rats or rabbits at exposures estimated to be 11 and 12 times the maximum recommended human dose, respectively. However, based on this drug's action to decrease cholesterol synthesis and other biologically active substances derived from cholesterol, this drug may cause fetal harm when administered to pregnant women. Hyperlipidemia is generally not a condition necessary to treat during pregnancy. There are no controlled data in human pregnancy.

US FDA pregnancy category Not Assigned: The US FDA has amended the pregnancy labeling rule for prescription drug products to require labeling that includes a summary of risk, a discussion of the data supporting that summary, and relevant information to help health care providers make prescribing decisions and counsel women about the use of drugs during pregnancy. Pregnancy categories A, B, C, D, and X are being phased out.

See references

Bempedoic acid Breastfeeding Warnings

Not Recommended

Excreted into human milk: Unknown
Excreted into animal milk: Unknown

Comments:
-Breastfeeding is not recommended due to the potential for serious adverse reaction in the breastfed infant.

This drug may cause harm to breast fed infant based on its mechanism of action. This drug decreases cholesterol synthesis and possibly the synthesis of other biologically active substances derived from cholesterol. There are no data on the effects of this drug on the breastfed infant or its effects on milk production, but due to the potential for serious adverse reactions, breastfeeding is not recommended.

See references

See also

References for pregnancy information

  1. Cerner Multum, Inc. "UK Summary of Product Characteristics."
  2. (2020) "Product Information. Nexletol (bempedoic acid)." Esperion Therapeutics

References for breastfeeding information

  1. Cerner Multum, Inc. "UK Summary of Product Characteristics."
  2. (2020) "Product Information. Nexletol (bempedoic acid)." Esperion Therapeutics

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer